Federal News Update: ARPA-H and Clinical Trial Modernization, the FDA’s Rare Disease Framework and Lame Ducks
While he’s a firm believer in the entire clinical trial process, for Carlos Orantes, Chief Executive Officer at Alcanza Clinical Research, there’s an unmistakable ‘magic’ to be found in late-stage trials. “You’re that much closer to bringing lifesaving and enhancing drugs and devices to patients by collaborating with other dedicated professionals,” he says.
Policy News Update: New FDA Commissioner Nominated and PDUFA Reforms Framework Released
While he’s a firm believer in the entire clinical trial process, for Carlos Orantes, Chief Executive Officer at Alcanza Clinical Research, there’s an unmistakable ‘magic’ to be found in late-stage trials. “You’re that much closer to bringing lifesaving and enhancing drugs and devices to patients by collaborating with other dedicated professionals,” he says.
Does Private Equity backing make a research site worse?
The Association for Multisite Research Corporations (AMRC) appreciates the opportunity to provide comments regarding FDA’s proposed Expedited Investigational New Drug (IND) Pilot Program. AMRC represents a nationwide network of leading clinical research organizations conducting research across a broad range of therapeutic areas and patient populations. Our members collectively operate 466 research sites across seven countries and engage millions of patients throughout the United States.
Your Sites Have Game-Changing Data (And You’re Not Asking for It)
Working hard, head down and concentrating on facing the next task or challenge, it can sometimes be easy to forget how important clinical trials are in the big picture of human health and their positive impact on alleviating suffering and prolonging the quality of life.
AMRC Response to the Cures in Care Initiative: Expanding Access Without Compromising Research Quality
Working hard, head down and concentrating on facing the next task or challenge, it can sometimes be easy to forget how important clinical trials are in the big picture of human health and their positive impact on alleviating suffering and prolonging the quality of life.
Federal News Update: AMRC and C3TI, and Trump’s FY2027 Budget Request
While he’s a firm believer in the entire clinical trial process, for Carlos Orantes, Chief Executive Officer at Alcanza Clinical Research, there’s an unmistakable ‘magic’ to be found in late-stage trials. “You’re that much closer to bringing lifesaving and enhancing drugs and devices to patients by collaborating with other dedicated professionals,” he says.
Federal News Update: FDA Real-Time Trials and Congressional Reform Efforts Gain Momentum
While he’s a firm believer in the entire clinical trial process, for Carlos Orantes, Chief Executive Officer at Alcanza Clinical Research, there’s an unmistakable ‘magic’ to be found in late-stage trials. “You’re that much closer to bringing lifesaving and enhancing drugs and devices to patients by collaborating with other dedicated professionals,” he says.
Federal Health Policy Update: Funding, FDA AI, and Drug Supply Chain Shifts
While he’s a firm believer in the entire clinical trial process, for Carlos Orantes, Chief Executive Officer at Alcanza Clinical Research, there’s an unmistakable ‘magic’ to be found in late-stage trials. “You’re that much closer to bringing lifesaving and enhancing drugs and devices to patients by collaborating with other dedicated professionals,” he says.
Federal News Update: FDA Trial Policy Changes and Q2 Health Policy Outlook
While he’s a firm believer in the entire clinical trial process, for Carlos Orantes, Chief Executive Officer at Alcanza Clinical Research, there’s an unmistakable ‘magic’ to be found in late-stage trials. “You’re that much closer to bringing lifesaving and enhancing drugs and devices to patients by collaborating with other dedicated professionals,” he says.
Federal News Update: FDA RTF decision, FY26 funding secured, and FDA Modernization Act 3.0
While he’s a firm believer in the entire clinical trial process, for Carlos Orantes, Chief Executive Officer at Alcanza Clinical Research, there’s an unmistakable ‘magic’ to be found in late-stage trials. “You’re that much closer to bringing lifesaving and enhancing drugs and devices to patients by collaborating with other dedicated professionals,” he says.
